secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001628280-26-025372
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine appoints Svetlana Makhni as CFO effective April 16, 2026
-----------------------------------------------------------------------

- Svetlana Makhni named CFO; base salary $495K, sign-on bonus $40K, target bonus 40%.
- Granted option to purchase 800K shares (time-based vesting over 4 years) and 100K milestone-based option.
- Allan Reine steps down as principal financial officer but remains CEO.
- Makhni has 20+ years biotech/healthcare CFO and investment banking experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026025372/0001628280-26-025372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026025372/prme-20260407.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-025372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer